Sex Differences in Type-2 Diabetes: Implications for Cardiovascular Risk Management

E-ISSN： 1873-4286|23|10|1471-1476

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.10, 2017-05, pp. : 1471-1476

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of Type 2 Diabetes Mellitus and Cardiovascular Risk: Lessons from Intervention Trials

By Yki-Järvinen H.

Drugs, Vol. 60, Iss. 5, 2000-11 ,pp. : 975-983

Adis International

Access to resources Recommend Favorite

Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus: An Update

By Marcel M.C. Hovens Jouke T. Tamsma Edith D. Beishuizen Menno V. Huisman

Drugs, Vol. 65, Iss. 4, 2005-01 ,pp. : 433-445

Adis International

Access to resources Recommend Favorite

Future anti-inflammatory metabolic and cardiovascular management of Type 2 diabetes mellitus

By Laight David W

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 11, 2003-11 ,pp. : 1683-1689

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk

By Younk Lisa M Uhl Lisa Davis Stephen N

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 6, 2011-06 ,pp. : 753-763

Informa Healthcare

Access to resources Recommend Favorite

Glycaemic management of type 2 diabetes

By Page Simon

Clinical Medicine, Vol. 4, Iss. 4, 2004-07 ,pp. : 302-306

Royal College Of Physicians

Access to resources Recommend Favorite